Equities

BioCardia Inc

BioCardia Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.99
  • Today's Change0.05 / 1.70%
  • Shares traded1.00
  • 1 Year change-92.39%
  • Beta1.3660
Data delayed at least 15 minutes, as of Jul 03 2024 17:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.

  • Revenue in USD (TTM)468.00k
  • Net income in USD-10.34m
  • Incorporated1994
  • Employees16.00
  • Location
    BioCardia Inc320 Soquel WaySUNNYVALE 94085United StatesUSA
  • Phone+1 (650) 226-0123
  • Fax+1 (650) 631-3731
  • Websitehttps://www.biocardia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Notable Labs Ltd311.00k-12.39m5.09m16.00--0.4405--16.35-2.31-2.310.06221.280.0142----19,437.50-56.70-52.02-74.10-62.0937.3060.19-3,984.24-3,636.93----0.0271---52.89-11.9365.13---50.69--
Creative Medical Technology Holdings Inc9.00k-5.28m5.12m4.00--0.557--568.46-3.74-3.740.00646.810.00070.4291--2,250.00-42.47-110.00-43.88--60.0065.82-58,624.33-7,961.1423.53--0.00---89.84-40.8647.88------
Lixte Biotechnology Holdings Inc0.00-4.69m5.22m3.00---------2.38-2.380.001.390.00----0.00-118.45-104.18-130.17-111.05-----------1,253.200.00------19.41------
Helix BioMedix, Inc.2.07m-2.58m5.28m8.00--3.38--2.56-15.60-15.6012.486.950.80471.874.55258,238.80-100.64-146.31-120.73-173.5768.9630.80-125.06-527.121.69-14.570.00--122.0792.8067.73---29.08--
Halberd Corp281.24k25.34k5.34m3.003.62--210.5418.990.00230.00230.0018-0.00020.14490.03032.52--1.31--4.58--50.00--9.01--0.26611.351.02--271.52---60.11------
Pasithea Therapeutics Corp0.00-16.10m5.40m8.00--0.2718-----14.03-14.170.0019.060.00----0.00-49.97---53.80--------------0.00-------32.23------
BioCardia Inc468.00k-10.34m5.44m16.00------11.63-7.04-7.040.3132-1.270.0954--4.4429,250.00-210.81-107.34-1,190.90-154.17-----2,208.76-1,779.24---------64.72-5.262.82---28.89--
Tron Pharmaceuticals Inc1.01m-549.47k5.50m50.00------5.45-0.0034-0.00340.0062-0.0508------20,191.00--------60.28---110.51--0.0417-433.32----0.3272---39.70------
Fresh Tracks Therapeutics Inc8.01m-5.69m5.55m4.00--0.5591--0.6934-1.38-1.381.491.660.7326----2,001,500.00-52.10-89.76-66.50-115.24-----71.12-442.61---1,272.000.00--15.3137.6273.02------
Hepion Pharmaceuticals Inc0.00-38.52m5.58m22.00--0.9582-----9.49-9.490.001.370.00----0.00-117.64-61.43-145.05-68.82-----------3,240.310.00-------7.92------
TFF Pharmaceuticals Inc885.71k-19.93m5.61m19.00--0.8596--6.33-10.20-10.200.43712.110.0647--3.7246,616.32-145.46-79.57-181.57-83.41-----2,249.83-8,687.66----0.00--48.01--33.13------
HST Global Inc0.00-141.11k5.72m1.00---------0.0269-0.02690.00-0.11930.00-------29,397.92-5,836.01---------------24.24---------0.7858------
Intelligent Bio Solutions Inc2.83m-10.03m5.74m17.00--0.4816--2.03-64.14-64.144.603.820.20412.697.77166,299.40-72.67-80.65-107.67-224.8423.33---356.09-948.541.87--0.0451--187.51367.97-28.00------
Transcode Therapeutics Inc0.00-17.06m5.75m10.00--1.10-----206.36-206.360.000.78930.00----0.00-264.82-133.14-721.90-181.26-----------148.050.00-------5.59------
Xenetic Biosciences Inc2.44m-4.47m5.77m4.00--0.6648--2.36-2.92-2.921.595.630.2116----611,240.00-38.71-48.91-41.54-52.82-----182.95-682.42----0.00--48.80--36.90------
CeCors Inc-100.00bn-100.00bn5.81m6.00---------------0.0163------------------------------------22.70------
Data as of Jul 03 2024. Currency figures normalised to BioCardia Inc's reporting currency: US Dollar USD

Institutional shareholders

6.73%Per cent of shares held by top holders
HolderShares% Held
CM Management LLCas of 31 Mar 202446.67k2.56%
The Vanguard Group, Inc.as of 31 Mar 202443.12k2.37%
Geode Capital Management LLCas of 31 Mar 202410.39k0.57%
Two Sigma Securities LLCas of 31 Mar 20247.41k0.41%
Family Management Corp.as of 31 Mar 20245.17k0.28%
BlackRock Fund Advisorsas of 31 Mar 20242.79k0.15%
Brown Advisory LLCas of 31 Mar 20242.21k0.12%
Commonwealth Equity Services LLCas of 31 Mar 20242.00k0.11%
Securities America Advisors, Inc.as of 31 Mar 20241.43k0.08%
SSgA Funds Management, Inc.as of 31 Mar 20241.40k0.08%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.